Condition: Breast Cancer · Sponsor: University of Michigan Rogel Cancer Center
The purpose of this research study is to determine the safety, tolerability and dose of Ribociclib when combined with adjuvant radiation in women with high-risk ER+ breast cancer. Once enrolled on study, patients will begin treatment with Ribociclib 400 mg daily at the same time as they initiate standard of care adjuvant radiation therapy- 50 Gy in 25 fractions or 42.56 Gy in 16 fractions +/- 10 Gy boost including comprehensive nodal. Paitents will continue treatment with Ribociclib for up to 6 weeks.
This description comes directly from the study's public registry record.
Cancer AnswerLine · 1-800-865-1125 · CancerAnswerLine@med.umich.edu
Always discuss trial participation with your own doctor first.
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| University of Michigan Health West | Wyoming, Michigan, United States | Recruiting |
| UHCMC Seidman Cancer Center | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996107